

# CURRICULUM VITAE

**Carlos E. Milla, MD**

## PERSONAL REFERENCES

Birthdate: September 19, 1961

Birthplace: Lima, Peru.

Business Address: Center for Excellence in Pulmonary Biology  
Department of Pediatrics  
Stanford University  
770 Welch Road  
Suite 350  
Stanford, CA 94304  
Phone (650) 723-5191  
Fax (650) 723-5201

e-mail Address: [cmilla@stanford.edu](mailto:cmilla@stanford.edu)

Web Page: [http://Med.Stanford.edu/profiles/Carlos\\_Milla](http://Med.Stanford.edu/profiles/Carlos_Milla)

**HIGH SCHOOL** CEP "La Inmaculada", Lima, Peru. 1973 - 1977

**COLLEGE** U.P. Cayetano Heredia, School of Sciences and  
Philosophy, Lima, Peru. April 1978 to March 1980.

**MEDICAL SCHOOL** U.P. Cayetano Heredia, School of Medicine, Lima, Peru.  
April 1980 to March 1986.

Clinical Clerkships: From July 1984 to March 1986 rotating clerkships in  
internal medicine, pediatrics, surgery, and obstetrics and  
gynecology at general hospitals in Lima, Peru.

Research Activities: From July to September 1985 Tropical Medicine elective in  
Nauta, Loreto (Peruvian amazon jungle).  
From April to November 1986 Clinical Research elective at  
the Renal Unit of A. Loayza Hospital, Lima, Peru.

Graduation: Physician and surgeon diploma conferred on November 12,  
1986.

## **POSTGRADUATE WORK**

1987 to 1988, Clinical Resident at the Instituto de Investigacion Nutricional (Nutrition Research Institute), Lima, Peru.

1988 to 1989, Clinical Research Fellow at the Instituto de Investigacion Nutricional (Nutrition Research Institute), Lima, Peru.

1993 to 1995, Graduate student at the University of Minnesota School of Public Health, Epidemiology major.

1995 - Doctoral student at the Graduate School of the University of Minnesota, Epidemiology major. (Advisor: Russell V. Luepker, MD, MS).

## **CERTIFICATIONS**

Educational Commission for Foreign Medical Graduates, 1989.

American Board of Pediatrics, 1992.

American Board of Pediatrics, Pulmonology sub-Specialty Board, 1996 (renewed 2003).

## **PROFESSIONAL**

### **LICENSE**

Minnesota Board of Medical Practice, 1992.

Medical Board of California, 2007.

## **PROFESSIONAL EXPERIENCE**

1989 - 1992 Resident in Pediatrics at the Children's Medical Center of Brooklyn, State University of New York Health Sciences Center at Brooklyn.

1992 - 1995 Fellow in Pediatric Pulmonology and Cystic Fibrosis care at the University of Minnesota Hospital and Clinics.

1993 - 2007 Active member of the Professional Staff, Children's Hospitals and Clinics- Minneapolis, Minneapolis, Minnesota.

1995 - 1996 Postdoctoral Fellow, Pulmonary and Critical Care Division, Department of Pediatrics, University of Minnesota.

1995 - 2007 Active member of the Medical Staff, Fairview-University Medical Center, Minneapolis, Minnesota.

1996 – 1999 Instructor, Pulmonary and Critical Care Division, Department of Pediatrics, University of Minnesota.

1997 - 1999 Co-Director, Cystic Fibrosis Center, Department of Pediatrics, University of Minnesota

- 1997 - 2007 Active member of the Medical Staff, Gillette Children's Specialty Healthcare, St. Paul, Minnesota.
- 1997 - 2007 Active member of the Medical Staff, Saint Paul Regions Hospital (formerly Saint Paul Ramsey Hospital), St. Paul, Minnesota.
- 1998 - 2007 Active member of the Medical Staff, Hennepin County Medical Center, Minneapolis, Minnesota.
- 1999 - 2007 Director, The Minnesota Cystic Fibrosis Center, University of Minnesota Medical School
- 2000 - 2007 Assistant Professor, Pulmonary and Critical Care Division, Department of Pediatrics, University of Minnesota.
- 2003 - 2004 Interim Co-Director, Pulmonary and Critical Care Division, Department of Pediatrics, University of Minnesota.
- 2007 - Associate Professor, Department of Pediatrics, Stanford University.
- 2007 - Active member of the Medical Staff, Lucile Packard Children's Hospital, Stanford, California.
- 2007 - Active member of the Medical Staff, Stanford Hospital and Clinics, Stanford, California.
- 2007 - 2008 Interim Director, Adult Cystic Fibrosis Program, Stanford University.
- 2008 - Co-Director, The Stanford Cystic Fibrosis Center at Lucile Packard Children's Hospital, Stanford University, California.

**AWARDS**

- 2005 Annalisa Marzotto Endowed Chair in Cystic Fibrosis Care, University of Minnesota Medical School
- 2005 CF Clinician of the Year Award  
Chiron Inc.
- 2007 Crandall Endowed Faculty Scholar in Pediatric Pulmonary Medicine, Stanford University School of Medicine

**MEMBERSHIPS**

American Academy of Pediatrics.

American Medical Association.  
American Physiological Society (*Elected member*)  
American Thoracic Society  
Society for Pediatric Research (*Elected member*)  
International Society for Heart and Lung Transplantation

## PUBLICATIONS

### Peer Reviewed Journals:

1. Secord E; **Milla CE**; Shah B. Picture of the month: Ecthyma Gangrenosum secondary to *Pseudomonas aeruginosa*. *Am J Dis Children* 1993, 147:795-796.
2. **Milla CE**; Wielinski C; Warwick WJ. High-strength pancreatic enzymes. *Lancet*, 1994; 343: 599.
3. **Milla CE**; Wielinski,C.; Regelmann, WE. Clinical significance of the recovery of *Aspergillus species* from the respiratory secretions of cystic fibrosis patients. *Pediatr Pulmonol* 1996; 21:6-10. (Editorial comment in: *Pediatr Pulmonol* 1996;21:1-2).
4. **Milla CE**, Doherty L, Raatz S, Schwarzenberg SJ, Regelmann WE, Moran AM. The glycemic response to varying carbohydrate:fat ratios of dietary supplements in cystic fibrosis. *J Parent Ent Nutr* 1996; 20:182-186.
5. Shreve MR, Johnson SJ, **Milla CE**, Wielinski CL, Regelmann WE. Ribotyping and endonuclease subtyping in the epidemiology of *Burkholderia cepacia*. *Am J Resp Crit Care Med* 1997; 155:984-989.
6. **Milla CE**, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. *Chest* 1998; 113:1230-1234. (Editorial comment in: *Chest* 113:1159-1161).
7. Anand IS, Prasad BA, Chugh SS, Rao KRM, Cornfield DN, **Milla CE**, Singh N, Singh S, Selvamurthy W. Effects of inhaled Nitric Oxide and oxygen in high altitude pulmonary edema. *Circulation* 1998; 98:2441-2445.
8. **Milla CE**. Long term effects of aerosolized rhDNase on the pulmonary disease progression of Cystic Fibrosis patients. *Thorax* 1998, 53:1014-1017. (Editorial comment in *Thorax* 53:1003).
9. Cornfield DN, Barbato J, Maynard RC, Guiang S, Derangier RA, **Milla CE**. Randomized controlled trial of low dose inhaled nitric oxide in the treatment of term and near term infants with respiratory failure and pulmonary hypertension. *Pediatrics* 1999; 104:1089-1094.

10. Haddad IY, Ponastalis-Mortari A, Ingbar DH, Yang S, **Milla C**, Blazar B. High levels of preoxynitrite are generated in the lungs of irradiated mice given cyclophosphamide and allogeneic T cells. A potential mechanism of injury after marrow transplantation. *Am J Resp Cell Mol Biol* 1999; 20 (6):1125-1135.
11. Saqueton CB, Miller RB, Porter VA, **Milla CE**, Cornfield DN. Nitric oxide causes perinatal pulmonary vasodilation through K<sup>+</sup> channel activation and requires intracellular calcium release. *American Journal of Physiology – Lung* 1999; 276:L925-L932.
12. **Milla CE**. Rh DNase in cystic fibrosis. *Lancet* 1999; 354 (9176):428.
13. **Milla CE**, Warwick WJ, Moran AM. Trends in pulmonary function in cystic fibrosis (CF) patients correlate with the results of oral glucose tolerance test at baseline. *Am J Resp Crit Care Med* 2000; 162:891-895.
14. Moran A, **Milla C**, Ducret R, Nair KS. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. *Diabetes* 2001; 50:1336-1343.
15. Yang S, **Milla CE**, Panostalkis-Moratri A, Ingbar DH, Blazar BR, Haddad IY. Human surfactant protein A suppresses T-cell dependent inflammation and attenuates the manifestations of idiopathic pneumonia syndrome in mice. *Am J Resp Cell Mol Biol* 2001; 24(5):527-536.
16. Figueroa V, **Milla CE**, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal Lipid Levels in Cystic Fibrosis. *Am J Clin Nutr* 2002; 75:1005-1011.
17. Moran A, Phillips J, **Milla CE**. Insulin and glucose excursion following pre-meal Insulin lispro or Repaglinide in cystic fibrosis related diabetes. *Diabetes Care* 2001; 24:1706-1710.
18. Yang S, Porter V, Cornfield DN, **Milla C**, Panostalkis-Mortari A, Blazar BR, Haddad IY. Effects of Oxidant Stress on Inflammation and Survival of iNOS Knockout Mice after Marrow Transplantation. *Am J Physiol : Lung* 2001; 281(4):L922-L930.
19. Cornfield DN, Tegtmeyer K, **Milla CE**, Sweeney M. Continuous propofol infusion in 142 critically ill children. *Pediatrics* 2002; 110(6):1177-1181.
20. Yang S, **Milla CE**, Panoskaltis-Mortari A, Hawgood S, Blazar BR, Haddad IY. Surfactant Protein-A (SP-A) decreases lung injury and mortality after Murine Marrow Transplantation. *Am J Respir Cell Mol Biol* 2002; 27: 297-305.

21. Peterson M, Jacobs D, **Milla CE**. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. *Pediatrics* 2003; 112:588-592.
22. Jackson A, Ternand C, Brunzell C, Kleinschmidt T, Dew D, **Milla CE**, Moran A. Insulin Glargine Improves Hemoglobin A1c in Children and Adolescents with Poorly Controlled Type 1 Diabetes. *Pediatric Diabetes* 2003; 4:64-69.
23. Cornfield DN, Haddad IY, **Milla CE**, Barbato JE, Park SJ. Safety of inhaled nitric oxide after lung transplantation. *J Heart Lung Transpl* 2003; 22:903-907.
24. Haddad IY, **Milla CE**, Yang S, Panoskaltis-Mortari A, Hawgood S, Lacey DL, Blazar BR. Surfactant Protein A mediates the protective effects of Keratinocyte Growth Factor after experimental marrow transplantation. *Am J Physiol : Lung Cell Mol Physiol* 2003:L602-610.
25. Moss RB, Rodman D, Spencer LT, Aitken M, Zeitlin P, Waltz D, **Milla CE**, Brody A, Clancy JP, Ramsey B, Hamblett N, Heald AE. Repeated AAV2 Aerosol-mediated CFTR Gene Transfer to the Lungs of Patients with Cystic Fibrosis: A Multicenter, Double-Blind, Placebo-Controlled Trial. *Chest* 2004; 125:509-521.
26. **Milla CE**, Hansen LG, Warwick WJ. High frequency chest compression: Comparison of the second and third generation compression waveforms. *Biomed Instrumentation Technol* 2004; 38:322-327.
27. **Milla CE**, Yang S, Cornfield DN, Brennan ML, Hazen S, Panoskaltis-Mortari A, Blazar B, Haddad IY. Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. *Am J Physiol : Lung Cell Mol Physiol* 2004; 287(4):L706-714 (Editorial comment in: *Am J Physiol : Lung Cell Mol Physiol* 287:L-704-705).
28. Garner HP, Perentesis JP, Boen JR, Phillips JR, Herron JG, Severson SJ, Kiffmeyer WR, **Milla CE**, Regelman WE. Circulating Neutrophil Peroxidase Activity Correlates with Sputum Peroxidase Activity, Sputum Production and Airflow Obstruction in Cystic Fibrosis. *J Lab Clin Invest* 2004; 144:127 - 133.
29. Moran A, Basu R, **Milla C**, Jensen MD. Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance. *Metabolism* 2004; 11:1467-1472.
30. Eikenberry M, Bartokova H, DeFor T, Haddad IY, Ramsay NKC, Blazar BR, **Milla CE**, Cornfield DN. Natural history of pulmonary complications in children following bone marrow transplantation. *Biol Blood Marrow Transpl* 2005; 11 (1): 56-64.

31. Deshpande AD, White TA, **Milla C**, Walseth TF, Lund FE, Kannan MS. CD38 regulates intracellular calcium and responsiveness to agonists in airway smooth muscle. *Am J Respir Cell Mol Biol* 2005; 32:149-156.
32. Shukla M, Yang S, **Milla C**, Panoskaltsis-Mortari A, Blazar B, Haddad IY. The absence of host tumor necrosis factor receptor 1 attenuates the manifestations of idiopathic pneumonia syndrome. *Am J Physiol : Lung Cell Mol Physiol* 2005; 288:L942-L949.
33. Deterding RR, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin P, **Milla CE**, Marshall B, LaVange L, Engels J, Mathews D, Schaberg A, Williams J, Ramsey B, for the Cystic Fibrosis Foundation Therapeutics Development Network. Safety and Tolerability of Denufosol Tetrasodium Inhalation Solution, a Novel P2Y<sub>2</sub> Receptor Agonist: Results of a Phase 1/Phase 2 Multi-Center Study in Mild to Moderate Cystic Fibrosis. *Pediatric Pulmonology* 2005; 39:339-348.
34. **Milla CE**, Billings JL, Moran A. Diabetes is associated with dramatically decreased survival in women but not men with cystic fibrosis. *Diabetes Care* 2005; 28:2141-2144.
35. Perdue DG, Cass OW, **Milla CE**, Dunitz J, Jessurun J, Sharp HL, Schwarzenberg SJ. Hepatolithiasis and Cholangiocarcinoma in Cystic Fibrosis. *Dig Dis Sci* 2007; 52(10):2638-42.
36. Gibson RL, Retsch-Bogart GZ, Oermann C, **Milla CE**, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. Microbiology, Safety, and Pharmacokinetics of Aztreonam Lysinate for Inhalation in Patients with Cystic Fibrosis. *Pediatric Pulmonology* 2006; 41(7):656-665.
37. Kharbanda S, Panoskaltsis-Mortari A, Haddad IY, Blazar BR, Orchard PJ, Cornfield DN, Grewal SS, Peters C, Regelman WE, **Milla CE**, Baker KS. Inflammatory Cytokines and the Development of Pulmonary Complications following Allogeneic Hematopoietic Cell Transplantation in Patients with Inherited Metabolic Storage Disorders. *Biol Bone Marrow Transpl* 2006; 12:430-37.
38. **Milla CE**, Hansen LG, Warwick WJ. Different frequencies should be prescribed for different High Frequency Chest Compression (HFCC) machines. *Biomed Instrumentation Technol* 2006; 40:319-324.
39. Kempainen R, Williams CB, Hazelwood A, Rubin B, **Milla CE**. Comparison of high frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis. *Chest* 2007, 132:1227-1232.

40. Moss RB, **Milla C**, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin H, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE. Repeated aerosolized AAV-CFTR for treatment of Cystic Fibrosis: a randomized placebo-controlled Phase 2B trial. *Human Gene Therapy* 2007, 18:726–732.
41. Berge JM, Patterson JM, Goetz D, **Milla CE**. Young Adults' Perceptions of living with Cystic Fibrosis during the transition to adulthood: A qualitative investigation. *Families, Systems and Health* 2007; 25(2):190-203.
42. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, **Milla CE**, Moran A. Microvascular Complications in Cystic Fibrosis Related Diabetes. *Diabetes Care* 2007; 30(5):1056-1051.
43. Patterson J, Wall M, Berge J, **Milla C**. Gender Differences in Treatment Adherence among Youth Living with Cystic Fibrosis: Development of a New Questionnaire. *J Cystic Fibrosis* 2008; 7:154-164.
44. Zirbes JM, **Milla CE**. Steroid-sparing effect of Omalizumab in the management of severe Allergic Bronchopulmonary Aspergillosis in children with cystic fibrosis. *Pediatric Pulmonology* 2008; 43:607–610.
45. Paterson JM, Berge J, Wall M, **Milla CE**. Associations of Psychosocial factors with Health Outcomes among youth with Cystic Fibrosis. *Pediatric Pulmonology* 2009; 44:46-53.
46. Harrison AN, Regelman WE, Zirbes JM, **Milla CE**. Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis. *Pediatric Pulmonology* 2009; 44:330-339.
47. Sabati AA, Kempainen RR, **Milla CE**, Ireland M, Blumenthal MN, Schwarzenberg SJ, Dunitz JM, Kahn KM. Gastroesophageal reflux in 201 adults with cystic fibrosis. (In press *J Cystic Fibrosis*).
48. Kempainen RR, Pytkas AM, Dunitz JM, Rimell FL, **Milla CE**. Lack of Effect of Functional Endoscopic Sinus Surgery on the Pulmonary Status of Adults with Cystic Fibrosis. (In review for publication, *Arch Otolaryngol*).
49. Sheridan MB, Wang N, Merlo C, **Milla C**, Borowitz D, Cutting GR, Mogayzel P. Identification of *CFTR* molecular defects in CF patients with one previously identified disease-causing mutation. (In review for publication *Chest*).
50. Kempainen RR, **Milla C**, Dunitz J, Hazelwood A, Williams C, Rubin BK, Billings JL. Comparison of settings used for High Frequency Chest Compression (HFCC) in cystic fibrosis. (In review for publication *Respiratory Care*).

51. Orchard PJ, **Milla C**, Braunlin E, DeFor T, Bjoraker K, Blazar BR, Peters C, Wagner J, Tolar J. Pre-transplant fecators affecting outcome in Hurler syndrome. (Submitted).

#### **Reviews:**

1. **Milla CE**. What is a Cystic Fibrosis pulmonary exacerbation? *Pediatr Pulmonol* 2003; S25: 146-147.
2. Kotlikoff MI, Kannan MS, Solway J, Deng KY, Deshpande DA, Dowell M, Feldman M, Green KS, Ji G, Johnston R, Lakser O, Lee J, Lund FE, **Milla C**, Mitchell RW, Nakai J, Rishniw M, Walseth TF, White TA, Wilson J, Xin HB, Woodruff PG. Methodologic advancements in the study of airway smooth muscle. *J Allergy Clin Immunol* 2004; 114:S18-31.
3. **Milla CE**. Association of nutritional status and pulmonary function in children with Cystic Fibrosis. *Curr Opin Pulm Med* 2004; 10:505 - 509.
4. Ferkol T, Rosenfeld M, **Milla CE**. Cystic Fibrosis pulmonary exacerbations. *Journal of Pediatrics* 2006; 148:259-264.
5. **Milla CE**. Cystic Fibrosis Related Diabetes. *Current Medical Literature – Diabetes* 2006; 23:33-38.
6. Zirbes JM, **Milla CE**. Cystic Fibrosis Related Diabetes. In Press, *Paediatric Respiratory Reviews*.
7. Matel J, **Milla C**. Nutrition in cystic fibrosis. In Press, *Seminars in Respiratory and Critical Care Medicine*.

#### **Book Chapters:**

1. **Milla CE**. Nutrition and lung disease in cystic fibrosis. In: Whittaker LA Ed., Cystic Fibrosis. *Clin Chest Med* 2007; 28:319-330.
2. **Milla CE**. Endocrine and metabolic disease. In: Turcios N and Fink R; Pulmonary Manifestations of Pediatric Systemic Disease. In Press, Elsevier, Philadelphia, PA.

#### **Editorials:**

1. **Milla CE**. Editorial: Allergic bronchopulmonary aspergillosis and cystic fibrosis. *Pediatric Pulmonology* 1999, 27:71-73.

2. Moran AM, **Milla CE**. Editorial. Abnormal glucose tolerance in cystic fibrosis: Why should patients be screened? *J Pediatrics* 2003; 142:97-99.

**Abstracts:**

1. **Milla CE**; Regelmann WE; Wielinski C. The distribution of the  $\Delta F508$  mutation in a group of deceased Cystic Fibrosis patients. *Am Rev Respir Dis* 1993; 147(4): A579.
2. **Milla CE**; Regelmann WE; Wielinski C. Comparison of the decline in pulmonary function in deceased cystic fibrosis patients homozygous for the  $\Delta F508$  mutation versus compound heterozygotes for the  $\Delta F508$  mutation. *Am Rev Respir Dis* 1993; 147(4): A464.
3. **Milla CE**; Wielinski C; Warwick WJ. Distal intestinal obstruction syndrome (DIOS) and association with pancreatic enzyme supplementation in a cohort of cystic fibrosis patients. *Pharmacoepidemiology* 1994; 3(S1):S30. (Presented at the 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden, 1994).
4. Wielinski C; **Milla CE**; Warwick WJ. Management effect due to the introduction of high potency pancreatic enzyme capsules (greater than 22,000 lipase units/capsule) for treatment of pancreatic insufficiency in cystic fibrosis. *Pharmacoepidemiology* 1994; 3(S1):S30. (Presented at the 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden, 1994).
5. **Milla CE**; Wielinski C, Warwick WJ. Survival analysis of a group of Cystic Fibrosis patients with FEV<sub>1</sub> below 30% of predicted. *Am J Resp Crit Care Med* 1994, 149:676.
6. **Milla CE**; Wielinski C, Regelmann WE. Clinical significance of *Aspergillus sp.* in CF respiratory secretions. *Pediatric Pulmonol* 1994; S10: 257.
7. **Milla CE**; Wielinski C, Zirbes JM, Warwick WJ. Clinical characteristics of cystic fibrosis (CF) patients waiting for lung transplantation. *Pediatric Pulmonol* 1994; S10: 270.
8. Warwick WJ, **Milla CE**; Wielinski C. Epidemiologic investigation of the incidence of gastrointestinal problems in a cohort of CF patients and its relation to the use of high strength pancreatic supplements. *Pediatric Pulmonol* 1995; 19:85-86.
9. **Milla CE**, Regelmann WE. Development of a new method to study intraphagocytic bacterial killing. *Pediatric Research* 1995, 37(p2):184A.

10. **Milla CE**, Wielinski CL, Warwick WJ. Potential usefulness of cyclosporine as an antiinflammatory drug in cystic fibrosis patients with advanced lung disease. *Am Journal Resp Crit Care Med* 1995, 151 (pt 2 of 2): A249.
11. Shreve MR, Johnson S, **Milla CE**, Wielinski C, Regelmann WE. Polymerase chain reaction based ribotyping and endonuclease subtyping are useful in determining *Burkholderia cepacia* transmission and blood stream invasion in cystic fibrosis patients. *Am Journal Resp Crit Care Med* 1995, 151 (pt 2 of 2): A740.
12. **Milla CE**, Doherty L, Raatz S, Schwartzberg SJ, Regelmann WE, Moran A. Glycemic and respiratory responses to enteral formulas containing varying amounts of fat and carbohydrate in a group of cystic fibrosis patients with severe pulmonary function impairment. *Pediatric Pulmonol* 1995; S12:261.
13. **Milla CE**, Wielinski CL, Jacobs D, Warwick WJ. Rate of decline in FEV<sub>1</sub> as a prognostic indicator among cystic fibrosis patients with different degrees of lung function impairment. *Am Journal Resp Crit Care Med* 1996, 153 (pt 2 of 2): A71.
14. Shreve MR, Johnson S, **Milla CE**, Wielinski C, Regelmann WE. Ribotyping and endonuclease subtyping in the epidemiology of *Burkholderia cepacia* *Am Journal Resp Crit Care Med* 1996, 153 (pt 2 of 2): A706.
15. **Milla CE**, Hite SH, Warwick WJ. Lung volume measurements in infants and young children with cystic fibrosis by a radiographic method. *Am Journal Resp Crit Care Med* 1997, 155 (pt 2 of 2): A646.
16. Shreve MR, **Milla CE**, Johnson AJ, Regelmann WE. Suitability of techniques of *P. aeruginosa* DNA fingerprinting to determine risk of acquisition in cystic fibrosis. *Pediatric Research* 1997, 41(pt2):A.
17. Haddad IY, Ponoskaltis-Mortari A, Ingbar D, **Milla CE**, Blazar B. Allogeneic T cells activate alveolar macrophages (AM) to produce autotoxic levels of Nitric Oxide during bone marrow transplantation (BMT). *Am Journal Resp Crit Care Med* 1998, 157 (3, pt 2 of 2): A272.
18. **Milla CE**, Warwick WJ, Moran A. Trends in pulmonary function in cystic fibrosis (CF) patients correlate with the results of oral glucose tolerance test at baseline. *Pediatr Pulmonol* 1998, S17:369.
19. **Milla CE**, Warwick WJ. Pulmonary function in infants with cystic fibrosis at the time of diagnosis and throughout the first 2 years of life. *Pediatr Pulmonol* 1998, S17:332.

20. Warwick WJ; Hansen LG; **Milla CE**. The improved sweat test, i.e. the Gibson-Cooke sweat test that is quantitative with 5 mg of sweat. *Pediatr Pulmonol* 1998, S17:698.
21. **Milla CE**, Regelman WE, Severson SJ, Warwick WJ. Risk factors associated with FEV<sub>1</sub> decline in cystic fibrosis (CF) patients with normal pulmonary function. *Pediatric Research* 1999, 45(4, pt. 2 of 2):353A.
22. **Milla CE**, Moran AM. Insulin Production at baseline influences the rate of decline in FEV<sub>1</sub> in cystic fibrosis patients without fasting hyperglycemia. *Pediatr Pulmonol* 1999; S19:305.
23. Zirbes JM, **Milla CE**. Lung transplantation for cystic fibrosis: ten year experience. *Pediatr Pulmonol* 1999; S19:294.
24. Moran AM, **Milla CE**, Ducret R, Nair S. Protein metabolism in clinically stable, well-nourished adult cystic fibrosis patients with abnormal glucose tolerance. . *Pediatr Pulmonol* 1999; S19:305.
25. **Milla CE**, Jacobs DR, Warwick WJ. Trends in FEV<sub>1</sub> and Body Mass Index (BMI) are strong predictors of death from pulmonary complications in patients with cystic fibrosis. *Pediatr Pulmonol* 1999; S19:338.
26. **Milla CE**, Hansen LG, Warwick WJ. Selection of frequencies for high frequency chest wall oscillation (HFCWO) in patients with cystic fibrosis (CF) must be individualized. *Am Journal Resp Crit Care Med* 2000, 161 (3, pt 2 of 2): A74.
27. Meyer CL, Adams A, Stone M, Polley C, **Milla C**. Measuring and predicting FRC and TLC in non-cooperative pediatric candidates for scoliosis correction surgery. (American Association for Respiratory Care International Respiratory Congress, 2000).
28. Warwick WJ, **Milla CE**. Cystic fibrosis after age 40. (23<sup>rd</sup> European Cystic Fibrosis Conference, Stockholm, Sweden, 2000).
29. Billings J, Dunitz JM, Warwick WJ, **Milla CE**. Long term survival of women with cystic fibrosis following pregnancy. *Pediatr Pulmonol* 2000; S20:312
30. Garner HP, Boen J, Perentesis J, Severson S, **Milla CE**, Regelman WE. Variability in Myeloperoxidase activity and protein content in circulating neutrophils from cystic fibrosis patients. *Pediatr Pulmonol* 2000; S20:262.
31. Figueroa V, Schwarzenberg SJ, **Milla CE**, Moran A. Isolated hypertriglyceridemia is Common in CF. *Pediatr Pulmonol* 2000; S20:325.

32. **Milla CE**, Adams A, Koop S, McCarty K, Polley K Meyer CL. Mechanical work of breathing in neurologically involved children with scoliosis. *Am Journal Resp Crit Care Med* 2001, 163 (5): A373.
33. Meyer C, Adams A, Koop S, McCarty K, Stone M, Marini J, **Milla C**. Lung restriction with scoliosis in pediatric candidates for corrective surgery. *Am Journal Resp Crit Care Med* 2001, 163 (5): A372.
34. **Milla CE**, Baker KS, Ramsay NKC, Cornfield DN. Changes in pulmonary function after bone marrow transplantation in children. *Am Journal Resp Crit Care Med* 2001, 163 (5): A856.
35. Hansen LG, Warwick WJ, Brown IV, **Milla CE**. A quantitative pilocarpine iontophoresis sweat chloride test in less than 30 minutes. (24<sup>th</sup> European Cystic Fibrosis Conference, 2001).
36. Warwick WJ, Hansen LG, **Milla CE**, Webe A, Seidlitz B, Locher M. The third generation waveform for airway clearance using high frequency chest wall oscillation (HFCWO) therapy. (24<sup>th</sup> European Cystic Fibrosis Conference, 2001).
37. **Milla CE**, Phillips J, Moran A. Insulin and Glucose Excursion Following Pre-Meal Insulin Lispro or Repaglinide in CFRD. *Pediatr Pulmonol* 2001; S22: 335.
38. Billings J, **Milla CE**. Risk factors for pneumothorax and prognostic implications in CF. *Pediatr Pulmonol* 2001; S22: 323.
39. Peterson M, Jacobs D, **Milla CE**. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. *Pediatr Pulmonol* 2001; S22: 327.
40. **Milla C E**, Moran A. M.Risk Of Mortality In Cystic Fibrosis (CF) Patients With Diabetes Is Associated With Gender And FEV1 At The Time Of Onset Of Diabetes. *Am Journal Resp Crit Care Med* 2002, 165 (8): A283.
41. Phillips J, Regelmann WE, **Milla CE**. A new minimally invasive technique to place agarose beads in the murine airway. *Am Journal Resp Crit Care Med* 2002, 165 (8): A509.
42. Peters C, Orchard PJ, Grewal SS, Shapiro EG, Ziegler RS, Charnas LR, Lockman LA, **Milla CE**, Dusenbery KE, Ahrens MJ, Davies SM, Johnson K, Abel SL, Ramsay NKC, Krivit W. Successful Long-term Treatment of alpha-Mannosidosis By Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) (44<sup>th</sup> American Society of Hematology meeting).
43. Warwick WJ, **Milla CE**. Cystic Fibrosis: Soon to be a geriatric problem. (25<sup>th</sup> European Cystic Fibrosis Conference, Genoa, Italy, 2002).

44. Moss R, Aitken M, Clancy J, **Milla CE**, Rodman D, Spencer T, Waltz D, Zeitlin P, Zoe D, Hamblett N, Johnson C, Pederson P, Carlin J. A Multicenter, Double-blind, Placebo Controlled, Phase II Study of Aerosolized tgAAVCF in Cystic Fibrosis Patients with Mild Lung Disease. *Pediatr Pulmonol* 2002; S24:250.
45. Kingsley DW, Herron J, Haddad IY, **Milla CE**. Burkholderia cepacia (BC) induces greater airway obstruction than Pseudomonas aeruginosa (PA) in a mouse model of chronic bronchial infection. *Am Journal Resp Crit Care Med* 2003, 167 (7): A916.
46. Shukla MA, Yang S, **Milla CE**, Panoskaltsis-Mortari A, Blazar BR, Haddad IY. Mechanisms of decreased lung injury in TNF receptor 1 (P55)-Deficient mice after allogeneic marrow transplantation. *Am Journal Resp Crit Care Med* 2003, 167 (7): A730.
47. Haddad IY, **Milla CE**, Hawgood S, Yang S, Panoskaltsis-Mortari A, Blazar BR. Surfactant protein A (SPA) is the mediator responsible for the pulmonary anti-inflammatory effects of keratinocyte growth factor after allogeneic marrow transplantation. *Am Journal Resp Crit Care Med* 2003, 167 (7): A935.
48. Kharbanda S, Baker S, Orchard PJ, Grewal SS, Ramsay NKC, Abel SL, **Milla CE**, Regelmann WE, Haddad IY, Panoskaltsis-Moratri A, Cornfield DN, Krivit W, Peters C. Bronchoalveolar lavage (BAL) before hematopoietic cell transplant (HCT) identifies infectious agents in pediatric metabolic storage disorder (MSD) patients. (*Presented at the 2003 Pediatric Academic Societies' Meeting, Seattle*).
49. Peterson ML, **Milla CE**. Growth potential as assessed by mid-parental height and pulmonary function in children with Cystic Fibrosis. *Pediatr Pulmonol* 2003; S25: 348.
50. **Milla CE**, Moran AM. Females with CF Related Diabetes are at higher risk for early mortality. *Pediatr Pulmonol* 2003; S25:352.
51. Dunitz JD, Warwick WJ, **Milla CE**. Clinical Characteristics of Cystic Fibrosis Patients Living Beyond Age 40. *Pediatr Pulmonol* 2003; S25: 336.
52. Billings JL, Moran AM, **Milla CE**. A menstrual cycle questionnaire in women with Cystic Fibrosis. *Pediatr Pulmonol* 2003; S25: 352.
53. Patterson JM, Wall M, **Milla CE**. Behavioral Risk Factors Associated with Morbidity Among Youth with Cystic Fibrosis. (*Presented at the 2004 SPP National Conference on Child Health Psychology*).

54. McKee E, Schissel K, Kleinschmidt T, **Milla C**. Implementation of an interdisciplinary management model for malnutrition in children with CF. *Pediatr Pulmonol* 2004; S27: 348.
55. Gibson RL, Retsch-Bogart G, Ahrens R, Clancy J, Daines C, **Milla C**, Oermann C, Pilewski J. Safety and tolerability of Aztreonam for inhalation in cystic fibrosis patients. *Pediatr Pulmonol* 2004; S27: 348.
56. Moss RB, **Milla C**, Colombo J, Clancy JP, Zeitlin P, Spencer T, Accurso F, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Martin D, Anklesaria P, Heald AE. A multicenter, double blind, placebo-controlled, Phase IIB study of aerosolized TGAAVCF for the treatment of cystic fibrosis. *Pediatr Pulmonol* 2004; S27: 348.
57. Schechter MS, **Milla C**, Sockrider M, Stark L, Luder E, White L, Powell D, Margolis P. Baseline characteristics do not predict early success by centers participating in a collaborative quality improvement project. *Pediatr Pulmonol* 2004; S27: 348.
58. Billings JL, Mullan B, Sharma S, Connett J, **Milla CE**. The effect of menarche on pulmonary function in women with cystic fibrosis. *Proc Am Thor Soc* 2005, 2: A180.
59. Moss RB, **Milla C**, Colombo J, Accurso F, Zeitlin P, Clancy JP, Spencer T, , Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Martin D, Anklesaria P, Heald AE. A multicenter, double blind, placebo-controlled, Phase IIB study of aerosolized TgAAV-CF as gene therapy for cystic fibrosis. *Proc Am Thor Soc* 2005, 2: A179.
60. Billings JL, **Milla CE**. Clinical characteristics associated with the presence of a CF pulmonary exacerbation. *Pediatr Pulmonol* 2005; S28: 311.
61. Sabati AA; Kempainen RR, **Milla CE**, Blumenthal MN, Schwarzenberg SJ, Dunitz JM, Khan KM. Gastroesophageal Reflux in cystic fibrosis. *Pediatr Pulmonol* 2005; S28: 342.
62. Billings JL, Carlquist D, **Milla CE**. Myostatin influences muscle mass and rate of pulmonary function decline among patients with Cystic Fibrosis (CF). 2006 Pediatric Academic Societies Meeting, *E-PAS2006:59:4831.100*.
63. Harrison AN, Regelman WE, **Milla CE**. Longitudinal analysis of pulmonary function in Cystic Fibrosis Infants. *Pediatr Pulmonol* 2006; S29:336.
64. Billings JL, Williams C, Sharma S, Connett J, **Milla CE**. Changes in pulmonary function through the menstrual cycle in women with CF. *Pediatr Pulmonol* 2006; S29:394.

65. Kempainen R, Hazelwood A, Williams C, Dunitz J, Billings JL, **Milla CE**. Comparison of airway clearance efficacy of sine and triangular wave High Frequency Chest Wall Oscillation (HFCWO) in patients with cystic fibrosis. *Pediatr Pulmonol* 2006; S29:351.
66. Powers A, Ahrens M, Zirbes J, Reigstad K, **Milla CE**. Early Minnesota Cystic Fibrosis Newborn Screening outcomes at the University of Minnesota and the incorporation of genetic counseling. *Pediatr Pulmonol* 2006; S29:273.
67. Christensen J, Reigstad K, Zirbes J, **Milla CE**, Harris J, Cossette S, Tharp D, Shelstad B, Mertz L. Parents and patients impacting CF Care. *Pediatr Pulmonol* 2006; S29:365.
68. Zirbes J, **Milla CE**. Experience with the use of Omalizumab (Xolair®) in the management of severe Allergic Bronchopulmonary Aspergillosis in 3 children with CF. *Pediatr Pulmonol* 2006; S29:339.
69. Deterding R, **Milla C**, Barnes M, Engels J, Koenig J, Williams C, Gorden J, Mathews D, Smiley L. Safety and Tolerability of Denufosol Inhalation Solution: Results of a 28-Day Phase 2 Study in 5-7 Year Old Patients with CF. *Pediatr Pulmonol* 2006; S29:306.
70. Sshwartz B, Moran A, Dunitz J, Billings J, Kempainen R, **Milla C**, Schwarzenberg SJ. Body mass index (BMI) and clinical outcomes in Cystic Fibrosis. *Pediatr Pulmonol* 2006; S29:388.
71. Powers A, Ahrens M, Zirbes J, Reigstad K, **Milla CE**. Minnesota Cystic Fibrosis Newborn Screening and the incorporation of genetic counseling. 2006 National Society of Genetic Counselors meeting, Nashville, TN.
72. Pylkas A, **Milla CE**, Dunitz J, Rasmussen L, Rimmel F, Kempainen R. Effect of functional endoscopic sinus surgery on the respiratory status of adults with cystic fibrosis. *Pediatr Pulmonol* 2007; S30:348.
73. Kuo CS, Zirbes JM, Conrad CK, Cornfield DN, **Milla CE**. Improved nutrition correlates with a decrease in air-trapping in infants with cystic fibrosis. (2008 PAS meeting, Hawaii).
74. Billings JL, Noren B, Williams CB, **Milla CE**. Safety and tolerability of inhaled sodium pyruvate as an antioxidant for patients with cystic fibrosis (CF). *Am J Respir Crit Care Med* 2008; 177: A455.
75. **Milla C**, Chmiel J, McCoy K, Accurso F, Billings J, Boyle M, Atkinson J, Liou T, Clancy JP, Pilewski J, Acton J, Pearce T. A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB-001 in cystic

- fibrosis patients infected with *Pseudomonas aeruginosa*. *Pediatr Pulmonol* 2008; S31:392.
- 76. Milla C**, Accurso F, Chmiel J, McCoy K, Billings J, Atkinson J, Clancy J, Liou T, Acton J, Lynch S, Burns J, Mayer-Hamblett N, Harris K, Patel R, Tremblay T, Parli T. A Phase I/II Study of the Anti-PcrV Antibody KB001 in Cystic Fibrosis Patients with *P. aeruginosa*. *Am J Respir Crit Care Med* 2009; 179: A1190.
- 77. Milla C**, Zirbes JM, Matel JL, Cornfield DN. Phenotypic characterization of infants with a genetic based diagnosis of CF. (Accepted, 2009 North American Cystic Fibrosis Conference).
- 78. Zirbes JM, Milla C**. Lung clearance index in infants with cystic fibrosis with the use of a novel ultrasonic device. (Accepted, 2009 North American Cystic Fibrosis Conference).
- 79. Milla C**, Chmiel JF, Accurso FJ, McCoy KS, Billings JL, Atkinson JJ, Clancy JP, Liou TG, Acton JD, Lynch SV, Slusher N, Burns JL, Hamblett-Mayer N, Harris JK, Patel R, Tremblay TM, Parli TJ. Anti-inflammatory effect of KB-001, an anti-PcrV antibody fragment, in CF patients chronically infected with *Pseudomonas aeruginosa*. (Accepted, 2009 North American Cystic Fibrosis Conference).
- 80. Zirbes J, Koepke R, Kharrazi M, Milla C**, California CF Newborn Screening Consortium. Sweat Chloride (SC) testing performance and concentration by mutation class among infants identified by Cystic Fibrosis (CF) Newborn Screening (NBS) in California. (Accepted, 2009 North American Cystic Fibrosis Conference).
- 81. Leigh MW, Davis SD, Zariwala M, Carson JL, Hazucha M, Ferkol T, Atkinson J, Sagel S, Rosenfeld M, Dell S, Olivier K, Milla C, Knowles MR**. Overview of the Genetic Disorders of Mucociliary Clearance Consortium. Advancing Rare Diseases Research Through Networks and Collaboration Conference, ORDR, NIH, Bethesda, MD July 16 2009.

## PRESENTATIONS

1. "Comparison of the decline in pulmonary function in deceased cystic fibrosis patients homozygous for the  $\Delta F508$  mutation versus compound heterozygotes for the  $\Delta F508$  mutation". Presented at the mini-symposium 'Cystic fibrosis: clinical studies', 1993 American Thoracic Society international conference, San Francisco, California, May 1993.
2. "Case presentation: Interaction of AIDS with cystic fibrosis in a 41 year old patient homozygous for  $\Delta F508$ ". Presented at the 'Fellows' clinical session', 7th North American Cystic Fibrosis Conference, Dallas, Texas, October 1993. (One

- of the seven presentations selected from a worldwide contest sponsored by the Cystic Fibrosis Foundation)
3. "A preventive medicine approach to asthma". Presented at the 4th Latin-American Pediatric Pulmonology Congress, Porlamar, Venezuela, September 1994.
  4. "Cystic fibrosis: diagnostic tools and therapeutic management". Presented at the 4th Latin-American Pediatric Pulmonology Congress, Porlamar, Venezuela, September 1994.
  5. "Development of a new method to study intraphagocytic bacterial killing". Presented at the Infectious Disease Session, 1995 Society for Pediatric Research meeting, San Diego, California, May 1995.
  6. "Potential usefulness of cyclosporine as an antiinflammatory drug in cystic fibrosis patients with advanced lung disease". Presented at the discussion session 'Airway Inflammation in Cystic Fibrosis', 1995 American Thoracic Society international conference, Seattle, Washington, May 1995.
  7. "Glycemic and respiratory responses to enteral formulas containing varying amounts of fat and carbohydrate in a group of cystic fibrosis patients with severe pulmonary function impairment". Presented at the workshop 'Latest Nutrition Research', 9th North American Cystic Fibrosis Conference, Dallas, Texas, October 1995.
  8. "Nutrition in the acutely ill cystic fibrosis patient with CO<sub>2</sub> retention". Presented at the workshop 'Gastrointestinal and metabolic complications in cystic fibrosis', 9th North American Cystic Fibrosis Conference, Dallas, Texas, October 1995.
  9. "Longitudinal studies in cystic fibrosis". Department of Pediatrics Grand Rounds, University of Minnesota, November 8 1995.
  10. "Update on Cystic Fibrosis Clinical Research". Department of Pediatrics Grand Rounds, University of Minnesota, August 26 1998.
  11. "Cystic Fibrosis for the Primary Practitioner". Department of Pediatrics Grand Rounds, St. Paul Regions Hospital, November 20 1998.
  12. "Respiratory Control Disorders in Children". Topics and Advances in Pediatrics Course, University of Minnesota, June 18 1999.
  13. "New Developments in Cystic Fibrosis". Department of Pediatrics Grand Rounds, University of Minnesota, October 27 1999.

14. "RSV Infection: What is new with an old problem?" Department of Pediatrics Grand Rounds, St. Paul Regions Hospital, February 11, 2000.
15. "RSV Bronchiolitis: current recommendations for treatment and prevention". Grand Rounds, Fariview Lakes Regional Area Hospital, November 3, 2000.
16. "Management of cystic fibrosis related diabetes: role of the pulmonologist". 14<sup>th</sup> North American Cystic Fibrosis Conference, Baltimore, Maryland, November 9, 2000.
17. "Can airway remodeling be modulated?" International Asthma Symposium, Lima, Peru, August 24 2001.
18. "Safety of inhaled corticosteroids use in children". International Asthma Symposium, Lima, Peru, August 25 2001.
19. "At what age could inhaled corticosteroids be started in children?" International Asthma Symposium, Lima, Peru, August 25 2001.
20. "Insulin and Glucose Excursion Following Pre-Meal Insulin Lispro or Repaglinide in CFRD". 15<sup>th</sup> North American Cystic Fibrosis Conference, Orlando, FL, October 26 2001.
21. "Current concepts in Acute Bronchiolitis". III Pediatric Pulmonology Congress, Venezuelan Society of Pediatric Pulmonology, Valencia, Venezuela, July 18 2002.
22. "Acute Asthma Crisis: Update on evaluation and management in Pediatrics". III Pediatric Pulmonology Congress, Venezuelan Society of Pediatric Pulmonology, Valencia, Venezuela, July 19 2002.
23. "Rationale for combination therapy in Pediatric Asthma". III Pediatric Pulmonology Congress, Venezuelan Society of Pediatric Pulmonology, Valencia, Venezuela, July 19 2002.
24. "State of the Art: Cystic Fibrosis". III Pediatric Pulmonology Congress, Venezuelan Society of Pediatric Pulmonology, Valencia, Venezuela, July 19 2002.
25. "Pulmonary complications in Children with Hurler's syndrome (MPS I)". 6<sup>th</sup> International COGENT meeting, Lucerne, Switzerland, September 15 2002.
26. "Innovative Care in Cystic Fibrosis: High Performing Centers". Improving Care for Children with CF Expert Meeting, New Orleans, October 2 2002.

27. "Body Mass and Pulmonary Function in Cystic Fibrosis". Research In Progress Conference, Pediatric and Adult Pulmonary Divisions Combined Conference, University of Minnesota Medical School, December 19, 2002.
28. "Clinical Information Systems – Using Data for Clinical Care". NICHQ Improving Care for Children with Cystic Fibrosis, Nashville, TN, February 6, 2003.
29. "Evidenced Based Care: Decision Support and Guidelines for Treatment: Nutrition". NICHQ Improving Care for Children with Cystic Fibrosis, Nashville, TN, February 7, 2003.
30. "Concept Proposal: Pharmacogenomics of Drug Responses in CF". Cystic Fibrosis Therapeutics Development Network, Spring Meeting, Seattle, WA, April 3, 2003.
31. "Delivery System Design: Building Effective Teams". NICHQ Improving Care for Children with Cystic Fibrosis, San Antonio, TX, April 7, 2003.
32. "Clinical Information Systems: Key components and CFF Patient Registry Implementation". NICHQ Improving Care for Children with Cystic Fibrosis, San Antonio, TX, April 7, 2003.
33. "Cystic Fibrosis Pulmonary Exacerbations" Session Chair. 17<sup>th</sup> North American Cystic Fibrosis Conference, Anaheim, California, October 17 2003.
34. "What is a Cystic Fibrosis pulmonary exacerbation?" 17<sup>th</sup> North American Cystic Fibrosis Conference, Anaheim, California, October 17 2003.
35. "Females with CF Related Diabetes are at higher risk for early mortality". 17<sup>th</sup> North American Cystic Fibrosis Conference, Anaheim, California, October 18 2003.
36. "Database development for patient care". NICHQ Improving Care for Children with Cystic Fibrosis, Houston, TX, November 17, 2003.
37. "Implementation of an interdisciplinary management model for malnutrition in children with CF". Cystic Fibrosis QI Leadership Collaborative, Baltimore, MD, January 26 2004.
38. "Data driven Quality Improvement: Experience with the Learning and Leadership Collaborative". 18<sup>th</sup> North American Cystic Fibrosis Conference, St Louis, Missouri, October 13 2004.

39. "Implementation of an interdisciplinary management model for malnutrition in children with CF". 18<sup>th</sup> North American Cystic Fibrosis Conference, St Louis, Missouri, October 15 2004.
40. "Pulmonary exacerbations in Cystic Fibrosis: Introduction" (Workshop Chair). 18<sup>th</sup> North American Cystic Fibrosis Conference, St Louis, Missouri, October 16 2004.
41. "Early lung disease: Improving the health of patients with Cystic Fibrosis". Early Intervention Educational Series. Eden Prairie, Minnesota, November 2 2004.
42. "Early lung disease: Improving the health of patients with Cystic Fibrosis". Early Intervention Educational Series. Chapel Hill, North Carolina, December 2 2004.
43. "Early lung disease: Improving the health of patients with Cystic Fibrosis". Early Intervention Educational Series. St Louis, Missouri, February 4 2005.
44. "Early lung disease: Improving the health of patients with Cystic Fibrosis". Early Intervention Educational Series. Salt Lake City, Utah, February 17 2005.
45. "Inflammation in the Cystic Fibrosis Lung". Cystic Fibrosis Inflammation Educational Series. Durham, North Carolina, April 21, 2005.
46. "Newborn Screening for Cystic Fibrosis". Advisory meeting for the Newborn Screening Program, Minnesota State Department of Health, St. Paul, MN, April 26, 2005.
47. "Inflammation in the Cystic Fibrosis Lung". Cystic Fibrosis Inflammation Educational Series. New York, New York, May 9, 2005.
48. "Gene Therapy for Cystic Fibrosis: Why, How and When?" Department of Pediatrics Grand Rounds, University of Minnesota Medical School, June 1, 2005.
49. "Inflammation in the Cystic Fibrosis Lung". Cystic Fibrosis Inflammation Educational Series. San Diego, California, June 8, 2005.
50. "Inflammation in the Cystic Fibrosis Lung". Cystic Fibrosis Inflammation Educational Series. Houston, Texas, July 14, 2005.
51. "Viral Bronchiolitis". 2005 International Pediatric Specialties Congress, Curitiba, Parana, Brazil, August 27 2005.
52. "Asthma, Rhinitis and the Influence of the Weather". 2005 International Pediatric Specialties Congress, Curitiba, Parana, Brazil, August 27 2005.

53. "Evaluation of the Child with Chronic Cough". 2005 International Pediatric Specialties Congress, Curitiba, Parana, Brazil, August 27 2005.
54. "Aggressive Nutritional Intervention Improves Survival in CF". 19<sup>th</sup> North American Cystic Fibrosis Conference, Baltimore, Maryland, October 21 2005.
55. "Innovative Approaches to Chronic Care in Pediatrics". Pediatrics Intelligence Conference, Chicago, Illinois, November 4 2005.
56. "Upcoming Statewide Newborn Screening for Cystic Fibrosis". Department of Pediatrics Grand Rounds, University of Minnesota Medical School, December 7, 2005.
57. "Filling the pipeline: Efficient Protocol Development and Lessons Learned". Cystic Fibrosis Therapeutics Development Network, Spring Meeting, Seattle, Washington, April 27, 2006.
58. "Respiratory Therapies in Cystic Fibrosis". 29<sup>th</sup> National Pediatric Congress, National Pediatric Confederation of Mexico, Guadalajara, Mexico, May 4 2006.
59. "Chronic Cough". 29<sup>th</sup> National Pediatric Congress, National Pediatric Confederation of Mexico, Guadalajara, Mexico, May 4 2006.
60. "Novel Approaches to the Assessment and Treatment of CF Lung Disease: Introduction". Session Chair, 2006 American Thoracic Society Meeting, San Diego, California, May 23 2006.
61. "Reviewing a Protocol". Introduction to CF Clinical Research Course, Denver, Colorado, November 1 2006.
62. "CF Pulmonary exacerbations". Roundtable moderator, 20<sup>th</sup> North American Cystic Fibrosis Conference, Denver, Colorado, November 4 2006.
63. "Overview of the Inflammatory Process in Cystic Fibrosis". 20<sup>th</sup> North American Cystic Fibrosis Conference, Denver, Colorado, November 4 2006.
64. "Respiratory Issues in Infants with Cystic Fibrosis". Newborn Screening for Cystic Fibrosis Workshop, Genetic Diseases Branch, California Department of Health, Richmond, California, March 22 2007.
65. "KB001 Human Antibody to Treat / Prevent *Pseudomonas* Infections: Clinical development plan". Cystic Fibrosis Therapeutics Development Network, Spring Meeting, Seattle, Washington, April 19, 2007.
66. "CF Related Diabetes and progression of lung disease". Pulmonary Medicine and Biology Grand Rounds, Stanford University, April 27 2007.

67. "Newborn Screening for Cystic Fibrosis: Introductory remarks". Western CF Consortium 2007 meeting, Los Angeles, California, June 23 2007.
68. "Pulmonary Function testing in Cystic Fibrosis: Infants to Adults". 21<sup>st</sup> North American Cystic Fibrosis Conference, Anaheim, California, October 3 2007.
69. "The inflammatory process in CF: A complex picture with many players. Introductory remarks". 21<sup>st</sup> North American Cystic Fibrosis Conference, Anaheim, California, October 6 2007.
70. "Improving Children's Health Through Expanded Newborn Screening and Preventative care: Cystic Fibrosis". Session moderator. Palo Alto, California, February 9 2008.
71. "A Phase I/II Study of KB-001 in Cystic Fibrosis Patients Infected with *Pseudomonas aeruginosa*". Cystic Fibrosis Therapeutics Development Network, Spring Meeting, Seattle, Washington, April 2, 2008.
72. "Accelerating the Rate of Improvement in Cystic Fibrosis Cares: Smart Change ideas for Pulmonary Care". Cystic Fibrosis QI Leadership Collaborative, Hartford, CT, June 3 2008.
73. "Transition to Adult Care Consensus Panel: Pediatric Perspective". California Cystic Fibrosis Consortium Spring Meeting, San Francisco, CA, June 6 2008.
74. "Progress in Cystic Fibrosis Research: Picking up the pace on the road to the cure". CFRI Annual Conference, Redwood City, CA, August 2 2008.
75. "CF NBS screen positive G542X/5T-12TG Case report". California CF NBS meeting, 22<sup>nd</sup> North American Cystic Fibrosis Conference, Orlando, FL, October 24 2008.
76. "How to make the most effective use of HFCWO". 22<sup>nd</sup> North American Cystic Fibrosis Conference, Orlando, FL, October 24 2008.
77. "Controlling infection in the Cystic Fibrosis patient". Cystic Fibrosis Community Case Exchange series. Chapel Hill, NC, November 6 2008.
78. "Nutrition and lung disease in Cystic Fibrosis". University of Tennessee, Le Bonheur Children's Medical Center, Cystic Fibrosis Conference. Memphis, TN, November 16 2008.
79. "Controlling infection in the Cystic Fibrosis patient". Cystic Fibrosis Community Case Exchange series. San Francisco, CA, November 18 2008.

80. "Lung Defense Mechanisms: Lessons Learned from Cystic Fibrosis". Department of Pediatrics Grand Rounds, Stanford University Medical School. Palo Alto, CA, December 19 2008.
81. "A Phase I/II Study of the Anti-PcrV Antibody KB001 in Cystic Fibrosis Patients with *P. aeruginosa*". Poster Discussion Session: New Data Regarding Cystic Fibrosis. 2009 American Thoracic Society Meeting. San Diego, CA, May 17 2009.
82. Pulmonology Platform Session. Session Co-Chair, 2009 Society for Pediatric Research meeting, Baltimore, MD, May 5 2009.
83. "Does IgE blockade have a role in the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA)?" ISHAM Working Group on Fungal Respiratory Infections in Cystic Fibrosis. Angers, France, June 8 2009.

#### **CURRENT RESEARCH ACTIVITIES**

1. Sweat Testing in CF Newborns detected by screening. Multicenter Study, Lead PI. Source: Cystic Fibrosis Foundation (MILLA08A0).
2. Newborn Screening Cystic Fibrosis Center at Stanford. Program Director. Source: State of California Department of Health (GDSP-08-CF012).
3. Translational CF Therapeutics Development Center at Stanford University. Lead PI. Source: Cystic Fibrosis Foundation (MILLA09Y0).
4. Genetic Disorders of Mucociliary Clearance. Site PI (Overall PI: Michael Knowles, MD). Source: NIH (5U154RR019480).
5. Infant Study of Inhaled Saline (ISIS). Multicenter study, Site PI (Overall PI: Stephanie Davies, MD and Margaret Rosenfeld, MD). Source: NHLBI 1U01HI092931-01 and Cystic Fibrosis Foundation.

#### **INDUSTRY SPONSORED CLINICAL RESEARCH**

1. Inhaled Sodium Pyruvate for the treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study. Multicenter study, Lead PI. Sponsor: Emphycorp Inc.
2. A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB-001 in Cystic Fibrosis Patients Infected with *Pseudomonas aeruginosa*. Multicenter Study, Lead PI. Sponsor: KaloBios Pharmaceuticals.

#### **OTHER ACTIVITIES:**

1. Expert Advisory Panel member to the NICHQ Breakthrough collaborative series project to improve outcomes in children with CF, (P.I.: Michael Schechter, Source: CF Foundation and NICHQ), 2002 – 2005.
2. Steering Committee Member, Cystic Fibrosis Foundation Therapeutics Development Network, 2002 – 2007.
3. Center Committee Member, Cystic Fibrosis Foundation, 2003 - Ongoing.
4. Accelerating Rate of Improvement in CF Care Leadership, Cystic Fibrosis Foundation, 2003 - Ongoing.
5. Member, Scientific Advisory Committee, University of Minnesota General Clinical Research Center, 2003 - 2006.
6. Special Review Panel for Microbiology Referral Centers, Cystic Fibrosis Foundation, May 2004.
7. Faculty of 1000 Medicine Project, Pediatric Respiratory Medicine Section Faculty member, 2004 – 2009.
8. Ad-Hoc Grant reviewer, Crohn's & Colitis Foundation of America, 2005.
9. Alternate Member, University of Minnesota Medical School Faculty Senate, 2005 - 2007.
10. Advisory Committee Member, Newborn Screening Program, Minnesota State Department of Health, 2005 – 2007.
11. Chair, Protocol Review Committee, Cystic Fibrosis Foundation Therapeutics Development Network, 2005 – Ongoing.
12. Cystic Fibrosis Foundation, Center Committee Task Force Member, November 2005.
13. Cystic Fibrosis Foundation, CF Pulmonary Exacerbations Consensus Conference Member, June 2006.
14. National Institutes of Health. NIDDK Special Emphasis Panel ZDK1 GRB-6 (J1): CF Research and Translational Core Centers (P30). January 2007.
15. Canadian Cystic Fibrosis Foundation, Research Subcommittee, External Grant Reviewer, 2007 – Ongoing.

16. American Heart Association. Grant Peer Review Committee; Lung, Resuscitation and Respiration Section, 2008 – Ongoing.
17. American Thoracic Society, ATS/ERS Joint Working Group on Infant/Preschool Lung Function. 2008 – Ongoing.
18. Admissions Review panel, Stanford University Medical School. 2008 – Ongoing.
19. Translational Research Centers Steering Committee Member, Cystic Fibrosis Foundation Therapeutics Development Network, 2009 – Ongoing.
20. Clinical Advisor, Sweat Rate Research Consortium, Cystic fibrosis Foundation Therapeutics, Inc. 2009 – Ongoing.
21. International Society for Human and Animal Mycology (ISHAM) Working Group on Fungal respiratory infections in cystic fibrosis. 2009 – Ongoing.